High efficacy of disopyramide in the management of ventricular fibrillation storms in a patient with Brugada syndrome

Pacing Clin Electrophysiol. 2010 Jun 1;33(6):e53-6. doi: 10.1111/j.1540-8159.2009.02665.x. Epub 2010 Jan 4.

Abstract

The patient was a 57-year-old man with Brugada syndrome, who had been implanted with a implantable cardioverter defibrillator (ICD). The frequency of ventricular fibrillation (VF) started to increase about 4 years after ICD implantation, occurring, at worst, six times in one night. Immediately after starting oral administration of disopyramide, VF stopped occurring. He then discontinued taking disopyramide, but immediately after the discontinuation VF started occurring again, so he restarted taking disopyramide. Thereafter, VF completely stopped occurring. Findings observed in our case suggest that disopyramide could be added in our arsenal of medications for treating arrhythmic storms in patient with Brugada syndrome.

Publication types

  • Case Reports

MeSH terms

  • Anti-Arrhythmia Agents / therapeutic use*
  • Brugada Syndrome / drug therapy*
  • Brugada Syndrome / therapy
  • Defibrillators, Implantable
  • Disopyramide / therapeutic use*
  • Electrocardiography
  • Humans
  • Male
  • Middle Aged
  • Quinidine / therapeutic use
  • Ventricular Fibrillation / drug therapy*
  • Ventricular Fibrillation / therapy

Substances

  • Anti-Arrhythmia Agents
  • Disopyramide
  • Quinidine